iTeos Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-112.64	96.65	214.52	-43.4	-26.54	-20.07
Depreciation & Amortization	0.9	0.8	0.6	0.54	0.61	0.51
Share-Based Compensation	27.02	21.56	13.79	4.29	0.81	0.11
Other Operating Activities	-19.03	-230.21	284.22	8.03	-2.11	-1.66
Operating Cash Flow	-103.76	-111.19	513.14	-25.18	-23.15	-19.1
Capital Expenditures	-2.97	-0.94	-1.18	-0.36	-0.72	-0.23
Change in Investments	75.72	-445	0	0	0	0
Other Investing Activities	-0.1	-0.12	-0.06	-0.02	-0.21	-0.07
Investing Cash Flow	72.66	-446.06	-1.24	-0.38	-0.93	-0.3
Share Issuance / Repurchase	1.11	0.93	2.94	211.27	0.1	0
Other Financing Activities	-	1.06	0.72	129.07	22.44	23.51
Financing Cash Flow	1.11	1.98	3.66	340.34	22.54	23.51
Exchange Rate Effect	-3.6	-8.53	-3.18	1.68	-0.53	-0.88
Net Cash Flow	-33.59	-563.8	512.38	316.46	-2.06	3.24
Free Cash Flow	-106.72	-112.13	511.96	-25.53	-23.87	-19.32
Free Cash Flow Margin	-847.34%	-41.90%	148.49%	-	-	-
Free Cash Flow Per Share	-2.98	-3.15	14.55	-1.69	-117.69	-31.42

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).